Form 8-K - Current report:
SEC Accession No. 0001193125-20-166779
Filing Date
2020-06-11
Accepted
2020-06-11 17:24:33
Documents
11
Period of Report
2020-06-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d941921d8k.htm 8-K 25311
2 EX-1.1 d941921dex11.htm EX-1.1 191757
3 EX-5.1 d941921dex51.htm EX-5.1 12801
4 EX-99.1 d941921dex991.htm EX-99.1 8010
5 EX-99.2 d941921dex992.htm EX-99.2 8443
6 GRAPHIC g941921g0611145312296.jpg GRAPHIC 1785
7 GRAPHIC g941921g0611145952608.jpg GRAPHIC 4023
8 GRAPHIC g941921g0611145952914.jpg GRAPHIC 4589
9 GRAPHIC g941921g0611150206290.jpg GRAPHIC 4023
10 GRAPHIC g941921g0611150206575.jpg GRAPHIC 4589
11 GRAPHIC g941921g96o08.jpg GRAPHIC 3070
  Complete submission text file 0001193125-20-166779.txt   278748
Mailing Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Business Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 650-210-2900
ChemoCentryx, Inc. (Filer) CIK: 0001340652 (see all company filings)

EIN.: 943254365 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35420 | Film No.: 20958038
SIC: 2834 Pharmaceutical Preparations